Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Pfizer says 2021 COVID-19 vaccine sales to top $33.5 billion, sees need for boosters

07/28/2021 | 01:54pm EDT
FILE PHOTO: Vial and syringe are seen in front of displayed Pfizer logo

(Reuters) - Pfizer Inc on Wednesday raised its 2021 sales forecast for its COVID-19 vaccine by 29% to $33.5 billion, and said it believes people will need a third dose of the shot developed with German partner BioNTech to keep protection against the virus high.

The company said it could apply for an emergency use authorization (EUA) for a booster dose as early as August.

Data showed that a third dose generated virus-neutralizing antibodies more than 5 times higher in younger people and more than 11 times higher in older people than from two doses against the more easily transmissible Delta variant of the virus.

"All in all, I think a third dose would strongly improve protection against infection, mild moderate disease, and reduce the spread of the virus," Chief Scientific Officer Mikael Dolsten said on a call to discuss quarterly results.

Dolsten added that the data suggested levels of antibodies could be boosted up to 100-fold when compared to levels before the third dose.

The company also posted a non-peer reviewed study https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1 on Wednesday suggesting the vaccine's efficacy declines over time, and had dropped to around 84% effectiveness from a peak of 96% four months after participants received their second dose.

Pfizer shares were up 3.5% at $43.57.

Pfizer's decision earlier this month to seek authorization for a third dose drew criticism from U.S. health regulators, who said there was not yet enough data to show booster shots are needed. Scientists from U.S. health agencies have since discussed additional doses for people with compromised immune systems.

Meanwhile, billions of people in other countries are still waiting for a first COVID-19 shot.

Even without boosters, the company's 2021 sales forecast is expected to move higher as it only accounts for 2.1 billion doses that it has committed to countries out of 3 billion it plans to make this year.

Pfizer said it has shipped over 1 billion doses of the vaccine since December. The U.S. drugmaker records most of the combined sales from the vaccine, and splits expenses and profit 50-50 with its German partner.

Pfizer, whose shot was authorized in the United States, Europe and other regions around the world in December of 2020, has won new orders as rivals such as AstraZeneca Plc and Johnson & Johnson have faced manufacturing and safety hurdles.

Pfizer also competes with U.S. mRNA vaccine maker Moderna Inc, which has not been able to scale up production as quickly as its much larger rival.


Graphic: Reported and projected sales of COVID-19 vaccines -

J&J last week estimated full-year COVID-19 vaccine sales of $2.5 billion, while Moderna has forecast $19.2 billion.

Pfizer and BioNTech plan next month to test a version of the vaccine specifically designed to take on the fast-spreading Delta variant, with the first batch already manufactured, Pfizer said. The variant now accounts for more than 80% of new U.S. COVID-19 cases and has also become dominant in many other countries.

The U.S. Food and Drug Administration recently asked Moderna to expand the size of its pediatric trial.

Pfizer Chief Executive Albert Bourla said the company expects to be able to stick to its timeline to apply for an EUA for the vaccine in children under 12 in September, despite also having been approached by the FDA about new study requirements.

"We are not changing right now our expectations," Bourla said. "If we need to do more in less time, we will try to accommodate that."

Pfizer also raised its estimates for overall full-year profit, with strong sales of blood thinner Eliquis, which it shares with Bristol Myers Squibb, and cancer drug Ibrance.

The vaccine is helping drive a large part of the company's forecast, but Pfizer's base business is also growing, said Mizuho analyst Vamil Divan.

Pfizer now expects full-year adjusted profit of $3.95 to $4.05 per share, up from its prior forecast of $3.55 to $3.65.

(Reporting by Manas Mishra in Bengaluru and Michael Erman in New Jersey; Editing by Sriraj Kalluvila and Bill Berkrot)

By Manas Mishra and Michael Erman


ę Reuters 2021
All news about MODERNA, INC.
09/26MODERNA : U.S. administers 390.1 mln doses of COVID-19 vaccines - CDC
RE
09/26MODERNA : U.S. CDC Says 183,670,870 Individuals Have Been Fully Vaccinated Against COVID-1..
RE
09/24INSIDER SELL : Moderna
MT
09/24MODERNA : COVID SCIENCE-Vaccinated pregnant women pass protective antibodies to babies
RE
09/24MODERNA : U.S. administers 388.6 mln doses of COVID-19 vaccines - CDC
RE
09/24MODERNA : U.S. CDC Says 182,958,696 Individuals Have Been Fully Vaccinated Against COVID-1..
RE
09/24MODERNA : CDC director says boosters needed to protect workers
RE
09/24Equities Fluctuate Midday as Real Estate, Tech Among Worst Performers
MT
09/24EXPLAINER : Who's eligible for Pfizer booster shots in US?
AQ
09/24WALGREENS BOOTS ALLIANCE : Who can get a COVID-19 vaccine booster in the United States?
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 333 M - -
Net income 2021 12 514 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 14,5x
Yield 2021 -
Capitalization 174 B 174 B -
EV / Sales 2021 7,90x
EV / Sales 2022 7,19x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 430,14 $
Average target price 307,77 $
Spread / Average Target -28,4%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353
PHARMARON BEIJING CO., LTD.79.90%25 236